TGFBR2 and chronic myelogenous leukemia, BCR-ABL1 positive: Hence, we suggest that genes included in these pathways may be used as markers for CML development (FOS, TGFBR2, TPX2) and CML resistance to therapy (LAPTM4B, HLTF, PIEZO2, CFH, CD109, ANGPT1).